Cellebrite DI (NASDAQ:CLBT) CEO Sells $1,626,242.88 in Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CEO Thomas Hogan sold 103,188 shares of Cellebrite DI stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $15.76, for a total transaction of $1,626,242.88. Following the completion of the sale, the chief executive officer owned 590,777 shares in the company, valued at $9,310,645.52. The trade was a 14.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Cellebrite DI Price Performance

Cellebrite DI stock opened at $16.61 on Tuesday. The firm has a 50-day moving average of $13.48 and a 200-day moving average of $14.57. Cellebrite DI Ltd. has a one year low of $11.02 and a one year high of $19.98. The company has a market cap of $4.14 billion, a price-to-earnings ratio of 48.91, a P/E/G ratio of 1.94 and a beta of 1.17.

Hedge Funds Weigh In On Cellebrite DI

A number of institutional investors have recently bought and sold shares of the business. Pacer Advisors Inc. lifted its position in shares of Cellebrite DI by 91.1% in the first quarter. Pacer Advisors Inc. now owns 7,607 shares of the company’s stock valued at $105,000 after buying an additional 3,626 shares during the last quarter. Alpine Woods Capital Investors LLC acquired a new position in shares of Cellebrite DI during the 1st quarter worth approximately $223,000. Evolutionary Tree Capital Management LLC raised its stake in Cellebrite DI by 22.6% in the 1st quarter. Evolutionary Tree Capital Management LLC now owns 183,473 shares of the company’s stock valued at $2,528,000 after acquiring an additional 33,829 shares during the period. Ashford Capital Management Inc. lifted its holdings in Cellebrite DI by 5.5% during the 1st quarter. Ashford Capital Management Inc. now owns 1,762,937 shares of the company’s stock valued at $24,293,000 after purchasing an additional 92,092 shares during the last quarter. Finally, Quantinno Capital Management LP acquired a new stake in Cellebrite DI during the 1st quarter valued at $150,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on CLBT. Wall Street Zen upgraded Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. DA Davidson began coverage on Cellebrite DI in a research note on Wednesday, May 27th. They set a “buy” rating and a $20.00 price objective on the stock. Weiss Ratings raised Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Finally, Needham & Company LLC decreased their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $21.40.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.